United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates

Abstract

After the placebo-controlled extension of the pivotal US trial of glatiramer acetate for the treatment of relapsing multiple sclerosis ended, 208 participants entered an open-label, long-term treatment protocol. Magnetic resonance imaging (MRI) was added to the planned evaluations of these subjects to determine the consequences of long-term treatment on MRI-defined pathology and evaluate its clinical correlates. Of the 147 subjects that remained on long-term follow-up, adequate images were obtained on 135 for quantitative MRI analysis. The initial imaging sessions were performed between June 1998 and January 1999 at 2447+61 days (mean+standard deviation) after the subject's original randomization. Clinical data from a preplanned clinical visit were matched to MRI within 3+51 days. At imaging, 66 patients originally randomized to placebo (oPBO) in the pivotal trial had received glatiramer acetate for 1476+63 days, and 69 randomized to active treatment with glatiramer acetate (oGA) were on drug for 2433+59 days. The number of documented relapses in the 2 years prior to entering the open-label extension was higher in the group originally randomized to placebo (oPBO=1.86+1.78, oGA=1.03+1.28; P=0.002). The annualized relapse rate observed during the open-label study was similar for both groups (oPBO=0.27, +0.45 oGA=0.28+0.40), but the reduction in rate from the placebo-controlled phase was greater for those beginning therapy with GA (oPBO reduced by 0.66+0.71, oGA reduced by 0.23+0.58; P=0.0002). One or more gadolinium enhancing lesions were found in 27.4% of all patients (number of distinct enhancements=1.16+2.52, total enhanced tissue volume=97+26 ml). The risk of having an enhancement was higher in those with relapses during the open-label extension (odds ratio 4.65, 95% confidence interval (CI) 2.0 to 10.7; P=0.001). The odds for finding an enhancement was 2.5 times higher for those patients originally randomized to placebo (CI 1.1 to 5.4; P=0.02) compared to those always on glatiramer acetate. MRI-metrics indicative of chronic pathology, particularly measures of global cerebral tissue loss (atrophy), were uniformly worse for those originally on placebo. These observations enrich our long-term follow up of the clinical consequences of treatment with glatiramer acetate to include its apparent effects on MRI-defined pathology. They show that the effect of glatiramer acetate on enhancements is definite, but modest, consistent with the drug's described mechanisms of action, and that a delay in initiating treatment results in progression of MRI-measured pathology that can be prevented.

Keywords

multiple sclerosis glatiramer acetate Copaxone copolymer 1 magnetic resonance imaging clinical trial

Get full access to this article

View all access options for this article.

References

Johnson KP et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group . Neurology 45: 1268-1276 .

Johnson KP et al. (1998) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group . Neurology 50: 701-708 .

Johnson KP et al. (2000) Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group . Multiple Sclerosis 6: 255-266 .

Bedell BJ , Narayana PA , Wolinsky JS. (1997) A dual approach for minimizing false lesion classifications on magnetic resonance images . Mag Res Med 37: 94-102 .

Wolinsky JS et al. (2000) Linomide in relapsing and secondary progressive MS: Part II: MRI results . Neurology 54: 1734-1741 .

Comi G , Filippi M , Wolinsky JS , and the European/Canadian Glatiramer Acetate Study Group . (2001) The European/Canadian multicenter, double blind, placebo controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing remitting multiple sclerosis . Ann Neurol, in press.

Duda PW et al. (2000) Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis . J Clin Invest 105: 967-976 .

Neuhaus O et al. (2000) Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to The lper 2cells . Proc Natl Acad Sci 97: 7452-7457 .

Aharoni R et al. (2000) Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1 . Proc Natl Acad Sci 97: 11472-11477 .

10.

Gran B et al. (2000) Mechanisms of immunomodulation by glatiramer acetate . Neurology 55: 1704-1714 .

11.

Miller DH et al. (1999) Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis . Ann Neurol 46: 850-859 .

12.

Simon JH et al. (1998) Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis . Ann Neurology 43: 79-87 .

13.

Li DK , Paty DW. (1999) Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis . Ann Neurol 46: 197-206 .

14.

Ge Y et al. (2000) Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: Quantitative MR assessment . Neurology 54: 813-817 .

15.

Fisher E et al. (1997) Knowledge-based 3D segmentation of MR images for quantitative MS lesion tracking . SPIE Med Imag 3034: 599-610 .

16.

Rudick RA et al. (1999) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsingremitting MS . Neurology 53: 1698-1704 .

17.

Losseff NA et al. (1996) Progressive cerebral atrophy in multiple sclerosis. A serial MRI study . Brain 119: 2009-2019 .

18.

Paolillo A et al. (1999) Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H . Neurology 53: 751-757 .

19.

Kappos L et al. (1999) Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis . Lancet 353: 964-969 .